Verteporfin PDT for non-standard indications—a review of current literature

Chan, Wai Man; Tk, Lim; Pece, Alfredo; Silva, Rufino; Yoshimura, Nagahisa

doi:10.1007/s00417-010-1307-z

Cited by 60 publications

(41 citation statements)

References 99 publications

(98 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, these results suggested that the oxidative/antioxidative balance shifts towards the antioxidative status and PDT with Verteporfin caused growth cycle arrest that helps to prevent further damage and give the cell time to repair the defect. These results agree with previous reports of Nowak-Sliwinska et al (2006) and Chan et al (2010). They concluded that, damaged endothelium is known to release procoagulant and vasoactive factors through the lipo-oxygenase (leukotriene) and cyclo-oxygenase (eicosanoids such as thromboxane) pathways, resulting in platelet aggregation, fibrin clot formation and vasoconstriction.…”

Section: Discussionsupporting

confidence: 93%

“…Verteporfin was used in conjunction with a laser to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by non-thermal red light laser in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels (Nowak-Sliwinska et al 2006;Chan et al 2010).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of protein change and oxidative stress index after photodynamic therapy of corneal neovascularization

Abdelkawi

Hassan²

2012

gpb

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the change in corneal protein and oxidative stress state after using photodynamic therapy (PDT) for treatment of experimental corneal neovascularization (NV) with benzoporphyrin derivative (BPD). One group was considered as control (N = 10 eyes), corneal NV was induced in 25 New Zealand male rabbits (N = 50 eyes) after placing silk sutures in the corneal limbus. Five rabbits with corneal NV were left without any treatment, and 20 rabbits were administered by intravenous injection with Verteporfin at a dose of 1.5 mg/kg. Diode laser (660 nm) was applied for 5 minutes with a power of 50 mW/cm 2 . For a period of 4 weeks, five rabbits were selected and sacrificed weekly (N = 10 eyes each). The corneas were isolated for determination of protein content, SDS-PAGE, total antioxidant capacity (TAC), total oxidative capacity (TOC), malondialdhyde (MDA) and oxidative stress index (OSI). The results indicated that corneal NV induced changes in the content and composition on the corneal protein and gradual improvement of the cornea after the 3 rd and 4 th week of PDT was detected. Furthermore, the oxidative/antioxidative balance shifted towards the antioxidative status that helped to prevent further damage.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Evaluation of protein change and oxidative stress index after photodynamic therapy of corneal neovascularization

Abdelkawi

Hassan²

2012

gpb

View full text Add to dashboard Cite

show abstract

“…A suspected higher frequency among Asians, Caucasians and Hispanics as compared to African Americans (Chan et al, 2010;Yannuzzi, 1987) was not confirmed in all studies (Desai et al, 2003). A more severe form of CSCR with lower visual acuity seems to affect the African American subjects.…”

Section: Epidemiologymentioning

confidence: 90%

Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis

Daruich

Matet

Dirani

et al. 2015

Progress in Retinal and Eye Research

818

996

View full text Add to dashboard Cite

Central serous chorioretinopathy (CSCR) is a major cause of vision threat among middle-aged male individuals. Multimodal imaging led to the description of a wide range of CSCR manifestations, and highlighted the contribution of the choroid and pigment epithelium in CSCR pathogenesis. However, the exact molecular mechanisms of CSCR have remained uncertain. The aim of this review is to recapitulate the clinical understanding of CSCR, with an emphasis on the most recent findings on epidemiology, risk factors, clinical and imaging diagnosis, and treatments options. It also gives an overview of the novel mineralocorticoid pathway hypothesis, from animal data to clinical evidences of the biological efficacy of oral mineralocorticoid antagonists in acute and chronic CSCR patients. In rodents, activation of the mineralocorticoid pathway in ocular cells either by intravitreous injection of its specific ligand, aldosterone, or by over-expression of the receptor specifically in the vascular endothelium, induced ocular phenotypes carrying many features of acute CSCR. Molecular mechanisms include expression of the calcium-dependent potassium channel (KCa2.3) in the endothelium of choroidal vessels, inducing subsequent vasodilation. Inappropriate or over-activation of the mineralocorticoid receptor in ocular cells and other tissues (such as brain, vessels) could link CSCR with the known co-morbidities observed in CSCR patients, including hypertension, coronary disease and psychological stress.

show abstract

“…Subfoveal choroidal neovascular degeneration (CNV) is another area of significant interest for PDT [152]. CNV can occur as a complication of inflammatory conditions [153] and a combination of verteporfin PDT and immunosuppression has shown promise for inflammatory subfoeval CNV [154][155][156][157][158]. Photodynamic therapy with verteporfin is currently the only photosensitizer that is approved by regulatory agencies for the treatment of CNV secondary to pathologic myopatia and has shown beneficial effects [159].…”

Section: Current Developmentsmentioning

confidence: 99%

Nanodrug applications in photodynamic therapy

Paszko

Ehrhardt

Senge

et al. 2011

Photodiagnosis and Photodynamic Therapy

326

215

View full text Add to dashboard Cite

SummaryPhotodynamic therapy (PDT) has developed over last century and is now becoming a more widely used medical tool having gained regulatory approval for the treatment of various diseases such as cancer and macular degeneration. It is a two-step technique in which delivery of a photosensitizing drug is followed by irradiation of light. Activated photosensitizers transfer energy to molecular oxygen which results in generation of reactive oxygen species which in turn cause cells apoptosis or necrosis. Although this modality has significantly improved quality of life and survival time for many cancer patients it still offers significant potential for further improvement. In addition to the development of new PDT drugs, the use of nanosized carriers for photosensitizers is a promising approach which might improve the efficiency of photodynamic activity and which can overcome many side effects associated with classic photodynamic therapy. This review aims at highlighting the different types of nanomedical approaches currently used in PDT and outlines future trends and limitations of nanodelivery of photosensitizers. PDT -photodynamic therapy; PGA -poly(glycolic acid); PGLA -poly(D,L-lactide-coglycolide); PLA -poly(lactic acid); PS -photosensitizer; PEG -polyethylene glycol; ALA  aminolevulinic acid; m-THPC  5,10,15,20-tetra-(m-hydroxyphenyl)chlorine; m-THPP  meso-tetra(p-hydroxyphenyl); PpIX  protoporphyrin; Hp  hematoporphyrin; Pc4  silicon phthalocyanine; Ig  immunoglobulin; Tf  transferrin; TfR  transferrin receptor; VEGF  vascular endothelial growth factor; EPR  enhanced permeability and retention effect; FRET  fluorescence resonance energy transfer; MRI  magnetic resonance imaging; RES  reticuloendothelial system; ROS  reactive oxygen species; NP  nanoparticle; ND -nanodiamonds; SNP  silica nanoparticle; AMD  age-related macular degeneration; CNV  choroidal neovascularization; PTT  photothermal therapy;

show abstract

Verteporfin PDT for non-standard indications—a review of current literature

Cited by 60 publications

References 99 publications

Evaluation of protein change and oxidative stress index after photodynamic therapy of corneal neovascularization

Evaluation of protein change and oxidative stress index after photodynamic therapy of corneal neovascularization

Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis

Nanodrug applications in photodynamic therapy

Contact Info

Product

Resources

About

Verteporfin PDT for non-standard indications—a review of current literature

Cited by 60 publications

References 99 publications

Evaluation of protein change and oxidative stress index after photodynamic therapy of corneal neovascularization

Evaluation of protein change and oxidative stress index after photodynamic therapy of corneal neovascularization

Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis

Nanodrug applications in photodynamic therapy

Contact Info

Product

Resources

About

Evaluation of protein change and oxidative stress index after photodynamic therapy of corneal neovascularization

Evaluation of protein change and oxidative stress index after photodynamic therapy of corneal neovascularization